Regulatory Telomir seeks FDA approval for Telomir-1 to treat breast cancer Pharmaceutical Business ReviewThe IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment.RegulatoryOncologyRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Business Review The IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment. RegulatoryOncologyRead full story Post navigation Previous: FDA points to liver injury with Amgen’s TavneosNext: Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026